Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

51.17 

-1.40 -2.7%

as of Mar 25 '19

52 Week Range:

40.55 61.03


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company primarily focuses on metabolic syndrome, pain, infectious diseases, cholesterol medication, anti-hypertension drugs, depression treatment, prescription drugs, OTC drugs, and diagnostics. Its primary products include Cymbalta, a serotonin and noradrenaline reuptake inhibitor used for the treatment of depression, anxiety, diabetic neuropathic pain, fibromyalgia pain, chronic lower back pain, and osteoarthritis pain; Intuniv, a selective a2 adrenergic receptor agonist to treat attention-deficit hyperactivity disorder; Xofluza, an anti-influenza agent; and Symproic, a cancer pain analgesic tablet. It has a research collaborative agreement with National University Corporation Kyoto University to focus on drug discovery and medical research for the treatment of psychiatric disorders; strategic collaboration with Sage Therapeutics, Inc. to develop and commercialize SAGE-217 for MDD and other indications; license and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics Inc.; and a strategic collaboration with Tetra Discovery Partners LLC for the clinical development and commercialization of BPN14770, a selective phosphodiesterase-4D allosteric inhibitor. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Equity (BVPS) 6.18
7.04
8.18
8.34
8.89
9.07
9.88
11.06
12.20
13.48
14.24
growth rate 13.9% 16.2% 2.0% 6.6% 2.0% 8.9% 11.9% 10.3% 10.5% 5.6%
Earnings BIT 63,557.00
50,366.00
91,407.00
108,179.00
115,219.00
growth rate -20.8% 81.5% 18.4% 6.5%
Avg.PE 18.30
20.43
16.49
growth rate 11.6% -19.3%
ROA 5.94
3.42
7.41
3.76
5.18
12.16
7.21
7.42
10.73
12.81
15.63
growth rate -42.4% 116.7% -49.3% 37.8% 134.8% -40.7% 2.9% 44.6% 19.4% 22.0%
ROE 7.29
4.81
11.86
5.98
8.06
17.46
9.41
9.34
13.55
16.25
19.37
growth rate -34.0% 146.6% -49.6% 34.8% 116.6% -46.1% -0.7% 45.1% 19.9% 19.2%
ROIC 7.31
3.49
8.89
4.60
6.35
14.59
8.54
8.76
12.70
15.28
18.18
growth rate -52.3% 154.7% -48.3% 38.0% 129.8% -41.5% 2.6% 45.0% 20.3% 19.0%
Cur. Ratio 4.59
2.64
3.75
3.21
2.94
2.72
3.22
3.83
4.38
3.79
5.39
growth rate -42.5% 42.1% -14.4% -8.4% -7.5% 18.4% 18.9% 14.4% -13.5% 42.2%
Quick Ratio 3.42
1.75
2.75
2.33
2.08
1.77
2.27
2.66
3.37
2.93
4.38
growth rate -48.8% 57.1% -15.3% -10.7% -14.9% 28.3% 17.2% 26.7% -13.1% 49.5%
Leverage 1.21
1.62
1.58
1.59
1.52
1.37
1.25
1.27
1.25
1.28
1.20
growth rate 33.9% -2.5% 0.6% -4.4% -9.9% -8.8% 1.6% -1.6% 2.4% -6.3%
Balance Sheet Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Acct.Receivable 67,896.00
64,266.00
70,556.00
65,162.00
59,302.00
53,204.00
growth rate -5.4% 9.8% -7.6% -9.0% -10.3%
Acct.Payable 10,734.00
9,627.00
11,572.00
11,050.00
11,943.00
8,016.00
growth rate -10.3% 20.2% -4.5% 8.1% -32.9%
Cur.Assets 266,845.00
253,130.00
259,948.00
315,611.00
343,384.00
391,266.00
growth rate -5.1% 2.7% 21.4% 8.8% 13.9%
Total Assets 574,882.00
584,803.00
602,900.00
639,638.00
670,271.00
722,500.00
growth rate 1.7% 3.1% 6.1% 4.8% 7.8%
Cash 21,575.00
34,238.00
50,784.00
80,230.00
107,847.00
140,106.00
growth rate 58.7% 48.3% 58.0% 34.4% 29.9%
Inventory 49,326.00
48,368.00
44,480.00
42,182.00
41,386.00
34,635.00
growth rate -1.9% -8.0% -5.2% -1.9% -16.3%
Cur.Liabilities 98,207.00
78,669.00
67,794.00
71,982.00
90,595.00
72,566.00
growth rate -19.9% -13.8% 6.2% 25.9% -19.9%
Liabilities 151,250.00
112,393.00
124,018.00
125,763.00
144,061.00
117,661.00
growth rate -25.7% 10.3% 1.4% 14.6% -18.3%
LT Debt 30,027.00
10,034.00
30,094.00
30,074.00
30,054.00
18,491.00
growth rate -66.6% 199.9% -0.1% -0.1% -38.5%
Equity 468,648.00
474,529.00
509,790.00
522,736.00
601,373.00
growth rate 1.3% 7.4% 2.5% 15.0%
Common Shares 338.00
335.00
335.00
335.00
335.00
335.00
335.00
334.00
331.00
328.00
323.00
growth rate -0.9% 0.0% 0.0% 0.0% 0.0% 0.0% -0.3% -0.9% -0.9% -1.5%
Cash Flow Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Capital Expenditures 12,769.00
6,960.00
10,640.00
8,175.00
10,434.00
5,880.00
growth rate -45.5% 52.9% -23.2% 27.6% -43.7%
Cash Dividends 14,718.00
16,060.00
18,216.00
22,112.00
24,235.00
growth rate 9.1% 13.4% 21.4% 9.6%
Cash From OA 59,276.00
79,496.00
45,604.00
102,290.00
111,903.00
129,790.00
growth rate 34.1% -42.6% 124.3% 9.4% 16.0%
FCF per Share 0.07
0.41
0.95
1.15
0.79
1.15
0.92
1.06
1.25
2.25
1.92
growth rate 485.7% 131.7% 21.1% -31.3% 45.6% -20.0% 15.2% 17.9% 80.0% -14.7%
FCF 3,958.00
17,920.00
39,745.00
45,254.00
25,485.00
37,991.00
62,100.00
32,225.00
87,190.00
88,644.00
112,778.00
growth rate 352.8% 121.8% 13.9% -43.7% 49.1% 63.5% -48.1% 170.6% 1.7% 27.2%
Income Statement Mar '08 Mar '09 Mar '10 Mar '11 Mar '12 Mar '13 Mar '14 Mar '15 Mar '16 Mar '17 Mar '18
Sales 282,903.00
289,717.00
273,991.00
309,973.00
338,890.00
344,667.00
growth rate 2.4% -5.4% 13.1% 9.3% 1.7%
Op.Income 66,837.00
63,557.00
50,366.00
91,407.00
108,179.00
115,219.00
growth rate -4.9% -20.8% 81.5% 18.4% 6.5%
IBT 64,869.00
82,050.00
97,453.00
122,695.00
137,377.00
growth rate 26.5% 18.8% 25.9% 12.0%
Net Income 66,837.00
41,831.00
44,060.00
66,687.00
83,879.00
108,866.00
growth rate -37.4% 5.3% 51.4% 25.8% 29.8%
EPS 74.21
71.23
115.33
59.80
80.91
199.17
121.23
132.04
201.70
255.87
337.43
growth rate -4.0% 61.9% -48.2% 35.3% 146.2% -39.1% 8.9% 52.8% 26.9% 31.9%
Gross Profit 204,329.00
211,724.00
191,802.00
235,215.00
261,113.00
270,756.00
growth rate 3.6% -9.4% 22.6% 11.0% 3.7%
R&D 51,924.00
48,870.00
49,787.00
59,907.00
59,945.00
growth rate -5.9% 1.9% 20.3% 0.1%

Quarterly Statements

Item Name Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Earnings BIT 34,368.00
25,094.00
27,647.00
29,659.00
40,118.00
growth rate -27.0% 10.2% 7.3% 35.3%
Balance Sheet Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Acct.Receivable 64,633.00
53,204.00
63,695.00
48,820.00
59,567.00
growth rate -17.7% 19.7% -23.4% 22.0%
Acct.Payable 9,654.00
8,016.00
6,824.00
9,167.00
10,175.00
growth rate -17.0% -14.9% 34.3% 11.0%
Cur.Assets 366,677.00
391,266.00
400,367.00
406,373.00
392,155.00
growth rate 6.7% 2.3% 1.5% -3.5%
Total Assets 704,588.00
722,500.00
738,654.00
745,079.00
718,607.00
growth rate 2.5% 2.2% 0.9% -3.6%
Cash 126,017.00
140,106.00
147,660.00
194,400.00
173,271.00
growth rate 11.2% 5.4% 31.7% -10.9%
Inventory 40,898.00
34,635.00
36,703.00
38,868.00
39,550.00
growth rate -15.3% 6.0% 5.9% 1.8%
Cur.Liabilities 62,038.00
72,566.00
78,478.00
72,590.00
72,608.00
growth rate 17.0% 8.2% -7.5% 0.0%
Liabilities 112,428.00
117,661.00
111,193.00
95,092.00
85,172.00
growth rate 4.7% -5.5% -14.5% -10.4%
LT Debt 24,057.00
18,491.00
18,486.00
3,173.00
growth rate -23.1% 0.0% -82.8%
Equity 588,697.00
601,373.00
622,944.00
645,577.00
629,029.00
growth rate 2.2% 3.6% 3.6% -2.6%
Common Shares 21,279.00
21,279.00
21,279.00
21,279.00
21,279.00
growth rate 0.0% 0.0% 0.0% 0.0%
Cash Flow Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Capital Expenditures
growth rate
Cash From OA
growth rate
FCF
growth rate
Income Statement Dec '17 Mar '18 Jun '18 Sep '18 Dec '18
Sales 91,190.00
81,305.00
88,524.00
79,679.00
97,039.00
growth rate -10.8% 8.9% -10.0% 21.8%
Op.Income 34,368.00
25,094.00
27,647.00
29,659.00
40,118.00
growth rate -27.0% 10.2% 7.3% 35.3%
IBT 39,498.00
32,972.00
40,071.00
32,100.00
46,235.00
growth rate -16.5% 21.5% -19.9% 44.0%
Net Income 29,391.00
29,139.00
31,892.00
26,004.00
36,448.00
growth rate -0.9% 9.5% -18.5% 40.2%
Gross Profit 74,138.00
64,117.00
76,611.00
66,868.00
81,383.00
growth rate -13.5% 19.5% -12.7% 21.7%
R&D 59,945.00
59,945.00
growth rate 0.0%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

B (81.30)

YOY Growth Grade:

C (55.32)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 14.83 15.49
EPS / Growth 3.30

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 9.6%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 9.6% 9.6% 9.6%
Future PE 0.01 11.33 11.33
Future EPS 8.25 8.25 8.25
Value Price
MOS %
0.02
-100.0%
23.10
-54.9%
23.10
-54.9%
MOS Price 0.01 11.55 11.55
IRT 9.35 9.35 9.35

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.